Journal
JOURNAL OF ANESTHESIA
Volume 34, Issue 5, Pages 729-740Publisher
SPRINGER JAPAN KK
DOI: 10.1007/s00540-020-02823-6
Keywords
Lung transplantation; Primary graft dysfunction; Reperfusion injury; Therapeutics
Categories
Funding
- NIAA, London, UK
Ask authors/readers for more resources
Primary graft dysfunction (PGD) is one of the most common complications in the early postoperative period and is the most common cause of death in the first postoperative month. The underlying pathophysiology is thought to be the ischaemia-reperfusion injury that occurs during the storage and reperfusion of the lung engraftment; this triggers a cascade of pathological changes, which result in pulmonary vascular dysfunction and loss of the normal alveolar architecture. There are a number of surgical and anaesthetic factors which may be related to the development of PGD. To date, although treatment options for PGD are limited, there are several promising experimental therapeutic targets. In this review, we will discuss the pathophysiology, clinical management and potential therapeutic targets of PGD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available